Amgen Inc. (AMGN) – Significant performance due to volume growth of key innovative products

in , on February 16, 2021

The company advanced their innovative pipeline, sotorasib and Tezepelumaba , both of which have received Breakthrough Therapy Designation from the FDA and it  is ready to launch Sotorasib upon approval and to establish it as a foundational therapy for patients with advanced lung cancer.

Highlights 

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance 

CrispIdea Coverage 

No of Pages : 39

Release Information

  • Released
    :

    February 16, 2021

  • Last Updated
    :

    February 17, 2021